Join to View Full Profile
101 The City Dr SSte 400Orange, CA 92868
Phone+1 714-456-5691
Dr. Fujimoto is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Dylann Fujimoto is an ophthalmologist based in Orange, CA. She completed her medical degree at the University of California, Irvine, School of Medicine in 2022 and is currently in her residency in ophthalmology at the same institution, scheduled from 2022 to 2026. She earned her BA in Molecular and Cellular Biology with Research Honors from the University of California, Berkeley in 2015. Her publications include topics ranging from ophthalmology, such as her work on Streptococcus pneumoniae endophthalmitis, to diverse medical research areas such as radiosurgery, compliance in gynecologic oncology treatment, AI in renal assessments, and health interventions for endometrial cancer survivors.
Education & Training
University of California (Irvine)Residency, Ophthalmology, 2022 - 2026
University of California, Irvine, School of MedicineClass of 2022
University of California, BerkeleyBA, Molecular and Cellular Biology, Research Honors, 2011 - 2015
Certifications & Licensure
CA State Medical License 2023 - 2025
Publications & Presentations
PubMed
- Effect of Subcutaneous Injection of Tranexamic Acid on Ecchymosis and Edema after Oculofacial Surgery: A Prospective, Randomized, Split-Face, Double-Blind Study.Teresa H Chen, Dylann Fujimoto, Eduardo Damous Feijó, Jose Eduardo Rios, Marisa Novaes de Figueiredo Rassi
Aesthetic Surgery Journal. 2025-03-11 - Streptococcus pneumoniae endophthalmitis after exposed glaucoma drainage implant.Dylann Fujimoto, Philina Yee, Stephanie Noh, Kapil Mishra, Sameh Mosaed
American Journal of Ophthalmology Case Reports. 2024-12-01 - 1 citationsPhase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities From Large Brain Metastases: Health-related Quality of Life Outcomes.Elham Rahimy, S.A. Dudley, Rie von Eyben, Erqi L. Pollom, Kira Seiger
American Journal of Clinical Oncology. 2021-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
